E-Cigarettes under the microscope: a safer switch for older smokers?
NCT ID NCT05144542
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This study looks at what happens when older smokers (ages 50-80) who are at high risk for lung cancer switch from regular cigarettes to e-cigarettes. Researchers will track how many cigarettes they smoke and measure health markers like inflammation in their blood. The goal is to help regulators understand the potential benefits and risks of this switch.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
135 people
The number who actually took part.
- Started
-
Mar 2022
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 50-80 years who currently smokes at least 1 or more combustible cigarettes per day OR who is a nondaily smoker (any self-reported smoking in the past 30 days) with a 20 pack-year history. * Being interested in trying ECs to change CC smoking behavior * Willing to have biospecimen samples taken, either in-home using a mobile phlebotomoty service, or at an approved collection site * Have an address where he/she can receive mail * Being fluent in spoken and written English * Agrees to comply with all MD Anderson institutional policies related to COVID-19 screening prior to any in-person research visit. * The individual agrees to not engage in study procedures or interactions with study personnel while operating a vehicle. Exclusion Criteria: * Individuals who report depressive symptoms in the moderately severe or severe range on the PHQ-9 (scores of 15 or above); or who report current suicidal ideation on the PHQ-9 * Have ever had a diagnosis of lung cancer, have uncontrolled or unstable medical condition (e.g., uncontrolled hypertension, angina, diabetes) * Unwilling to consent for blood draw * Evidence of cognitive deficits or instability that would preclude reliable study participation * Being pregnant, engaging in breast-feeding, or being of childbearing potential and engaging in sexual activity that could lead to pregnancy and is not protected by a medically acceptable, effective method of birth control while enrolled in the study, as determined by self-report. Medically acceptable contraceptives include: (1) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (2) barrier methods (such as a condom or diaphragm) used with a spermicide, or (3) an intrauterine device (IUD). Contraceptive measures sold for emergency use after unprotected sex are not acceptable methods for routine use. * Considered by the investigator to be an unsuitable or unstable candidate (including but not limited to the following situations: unwilling or unable to comply with study procedures) * Individuals who reside in an area that is outside of our shipping company or mobile phlebotomty contractors' areas of operation or in a jurisdiction outside of our medical staff's licensure (if unable to attend in-person clinic visits) AND who decline to come in to clinic to provide necessary samples and/or collect study products.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new tracers make many cancers light up on scans?
- Can tumor avatars reveal why cancer hits minorities harder?
- New PET tracer could spot cancers that standard scans overlook
- Can a conversation aid empower lung cancer patients?
- Can couples coping together ease the burden of advanced cancer?
- Can a custom toolkit help indigenous smokers spot lung cancer earlier?